Connect Biopharma Holdings annual r&d spending
2021
2022
2023
2024
2025
Connect Biopharma Holdings R&D Spending Growth & History (CNTB)
Connect Biopharma Holdings's r&d spending was $37.8M for fiscal 2025.
View full Connect Biopharma Holdings company overviewConnect Biopharma Holdings annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $37.8M | $8.5M | +29.20% |
| 2024 | 2024-12-31 | $29.3M | −$23.7M | −44.80% |
| 2023 | 2023-12-31 | $53.0M | −$43.6M | −45.15% |
| 2022 | 2022-12-31 | $96.6M | $16.1M | +20.04% |
| 2021 | 2021-12-31 | $80.5M | — | — |
Connect Biopharma Holdings quarterly r&d spending
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $16.3M | $7.5M | +85.49% |
| Q1 2026 | 2026-03-31 | $15.0M | $8.4M | +126.59% |
| Q4 2025 | 2025-12-31 | $11.3M | $5.0M | +80.92% |
| Q3 2025 | 2025-09-30 | $11.1M | $2.1M | +23.32% |
| Q2 2025 | 2025-06-30 | $8.8M | $3.4M | +64.04% |
| Q1 2025 | 2025-03-31 | $6.6M | −$2.0M | −23.43% |
| Q4 2024 | 2024-12-31 | $6.2M | — | — |
| Q3 2024 | 2024-09-30 | $9.0M | — | — |
| Q2 2024 | 2024-06-30 | $5.3M | — | — |
| Q1 2024 | 2024-03-31 | $8.7M | — | — |
Connect Biopharma Holdings r&d spending trends
Between the periods ended 2021-12-31 and 2025-12-31, Connect Biopharma Holdings's r&d spending decreased from $80.5M to $37.8M, a change of −$42.7M. The latest reported quarter, Q2 2026, shows $16.3M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Connect Biopharma Holdings source filings ↗